company background image
688606 logo

Hangzhou Alltest Biotech SHSE:688606 Stock Report

Last Price

CN¥49.71

Market Cap

CN¥3.8b

7D

-3.9%

1Y

-5.7%

Updated

21 Jun, 2024

Data

Company Financials

Hangzhou Alltest Biotech Co., Ltd.

SHSE:688606 Stock Report

Market Cap: CN¥3.8b

688606 Stock Overview

Engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally.

688606 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends3/6

Hangzhou Alltest Biotech Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hangzhou Alltest Biotech
Historical stock prices
Current Share PriceCN¥49.71
52 Week HighCN¥81.10
52 Week LowCN¥46.02
Beta0.36
11 Month Change-14.19%
3 Month Change-17.82%
1 Year Change-5.69%
33 Year Change-48.29%
5 Year Changen/a
Change since IPO-57.70%

Recent News & Updates

Here's What's Concerning About Hangzhou Alltest Biotech's (SHSE:688606) Returns On Capital

Jun 08
Here's What's Concerning About Hangzhou Alltest Biotech's (SHSE:688606) Returns On Capital

There Are Some Holes In Hangzhou Alltest Biotech's (SHSE:688606) Solid Earnings Release

May 03
There Are Some Holes In Hangzhou Alltest Biotech's (SHSE:688606) Solid Earnings Release

Optimistic Investors Push Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) Shares Up 27% But Growth Is Lacking

Apr 25
Optimistic Investors Push Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) Shares Up 27% But Growth Is Lacking

Recent updates

Here's What's Concerning About Hangzhou Alltest Biotech's (SHSE:688606) Returns On Capital

Jun 08
Here's What's Concerning About Hangzhou Alltest Biotech's (SHSE:688606) Returns On Capital

There Are Some Holes In Hangzhou Alltest Biotech's (SHSE:688606) Solid Earnings Release

May 03
There Are Some Holes In Hangzhou Alltest Biotech's (SHSE:688606) Solid Earnings Release

Optimistic Investors Push Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) Shares Up 27% But Growth Is Lacking

Apr 25
Optimistic Investors Push Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) Shares Up 27% But Growth Is Lacking

Shareholder Returns

688606CN Medical EquipmentCN Market
7D-3.9%-2.4%-1.6%
1Y-5.7%-15.6%-15.7%

Return vs Industry: 688606 exceeded the CN Medical Equipment industry which returned -15.6% over the past year.

Return vs Market: 688606 exceeded the CN Market which returned -15.7% over the past year.

Price Volatility

Is 688606's price volatile compared to industry and market?
688606 volatility
688606 Average Weekly Movement7.1%
Medical Equipment Industry Average Movement6.0%
Market Average Movement6.7%
10% most volatile stocks in CN Market10.1%
10% least volatile stocks in CN Market4.2%

Stable Share Price: 688606's share price has been volatile over the past 3 months.

Volatility Over Time: 688606's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20091,093Fei Gaowww.alltests.com.cn

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, VTM, blood glucose monitoring systems, and HB hemoglobin test meters.

Hangzhou Alltest Biotech Co., Ltd. Fundamentals Summary

How do Hangzhou Alltest Biotech's earnings and revenue compare to its market cap?
688606 fundamental statistics
Market capCN¥3.79b
Earnings (TTM)CN¥184.83m
Revenue (TTM)CN¥718.48m

20.9x

P/E Ratio

5.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688606 income statement (TTM)
RevenueCN¥718.48m
Cost of RevenueCN¥368.67m
Gross ProfitCN¥349.81m
Other ExpensesCN¥164.98m
EarningsCN¥184.83m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)2.38
Gross Margin48.69%
Net Profit Margin25.73%
Debt/Equity Ratio0%

How did 688606 perform over the long term?

See historical performance and comparison

Dividends

3.0%

Current Dividend Yield

64%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.